Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression
Rheumatic Disease Clinics of North America · 2024
DOI: 10.1016/j.rdc.2024.01.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatic Disease Clinics of North America, 2024. Verfasst von Jeffrey A Sparks. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, 60 Fenwood Road, Suite 6016U, Boston, MA …. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Autoimmune Diseases, Disease Progression. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Bristol-Myers Squibb, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Themen: Patientensicherheit
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) are increasingly used to treat a variety of cancer types. Patients with preexisting autoimmune diseases may be vulnerable to underlying disease flare as well as immune-related adverse events from ICIs. There has also been concern that immunosuppression needed to control the autoimmune disease may blunt ICI efficacy. Much of the literature is focused on diverse preexisting autoimmune diseases, which may limit conclusions to specific diseases. There is a growing literature of specific diseases, such as preexisting rheumatoid arthritis, investigating outcomes after ICI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, 60 Fenwood Road, Suite 6016U, Boston, MA 02115, USA. Electronic address: jsparks@bwh.harvard.edu.
Förderung
- Bristol-Myers Squibb
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Sparks, J. A. (2024). Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression. Rheumatic Disease Clinics of North America. https://doi.org/10.1016/j.rdc.2024.01.001
Vancouver
Sparks JA. Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression. Rheumatic Disease Clinics of North America. 2024. doi:10.1016/j.rdc.2024.01.001
BibTeX
@article{Sparks2024,
author = {Sparks, Jeffrey A},
title = {Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression},
journal = {Rheumatic Disease Clinics of North America},
year = {2024},
doi = {10.1016/j.rdc.2024.01.001}
}
EUVIMED